Rodman & Renshaw initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $48 price target The firm says the opportunity arising from the dual-targeting mechanism of ficerafusp and a higher probability for success in PD-L1-positive head and neck cancers provide for the majority of its valuation for the shares.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX: